NRC

NRC HealthB

Nasdaq / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$20.00

+2.1% vs current

Most likely

Base case

45%

Probability

Target price

$17.50

-10.7% vs current

B-

Bear case

25%

Probability

Target price

$14.50

-26.0% vs current

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

Headline flow is elevated because March-April 2026 included a business update, a buyback announcement in news coverage, the April 28 earnings release, and a separate compensation-related 8-K. Despite the queue labeling this as a T+3 follow-up, the earnings date was April 28, 2026 and the run date is April 29, 2026, so this is effectively an early post-print read with limited analyst-revision evidence. Immediate trusted secondary coverage suggested only a slight negative aftermarket reaction, which fits a cautious monitoring stance rather than a strong rerating call.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-28eventQ2 reported earnings face a known compensation and tax headwindHigh impact

A separate April 28, 2026 8-K disclosed amendments to executive equity awards and related tax gross-up bonuses that are expected to create about $9.4 million of Q2 2026 expense, including roughly $6.5 million of accelerated non-cash equity compensation and about $2.9 million of cash bonus expense, with an expected tax-rate impact [#8-K-2026-04-28].

2026-07-28catalystQ1 earnings confirmed improving growth and record TRCVMedium impact

NRC’s April 28, 2026 earnings 8-K and attached release reported Q1 revenue up 4% year over year to $34.8 million, GAAP EPS of $0.14, cash flow from operations of $7.2 million, and TRCV up 13% year over year to $152.1 million, with management calling it the first quarter of year-over-year revenue growth since 2023 [#8-K-2026-04-28-Earnings].

2027-04-29catalystTRCV momentum needs to convert into sustained revenue growthHigh impact

NRC’s March 4, 2026 business update said TRCV surpassed $152 million, up 6% from year-end 2025 and 13% year over year, and the Q1 release later confirmed $152.1 million at quarter-end; if that recurring-contract base converts into multi-quarter revenue and cash-flow expansion, the recovery thesis can strengthen materially [#PR-2026-03-04] [#8-K-2026-04-28-Earnings].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology